Just saw that Ionis got EU approval for Dawnzera - it's for hereditary angioedema prevention in people 12+. Basically this rare genetic condition causes sudden swelling that can get pretty serious, and this drug is supposed to cut down on the attacks. They already had US clearance last year, so the European nod is kind of the next step. Pretty interesting that Otsuka has the exclusive rights over there and Asia-Pacific. Ionis is pocketing $15 million upfront plus royalties up to 30% on sales, which sounds decent for a rare disease drug. IONS stock was up like 1.5% when I checked. Wondering if this opens up more opportunities in the rare disease space or if it's just a solid win for their pipeline.